In person Molecular glues and targeted protein degraders are revolutionizing the field of drug discovery, offering promising solutions for a range of diseases, including cancer, infectious, inflammatory, and neurodegenerative diseases. These innovative therapies are particularly beneficial for targeting previously “undruggable” pathogenic proteins. The recent emergence of the ‘molecular glue’ class of protein degraders is paving…

In person Starting from Sunday, November 10th, the ZoBio team participated in the 32nd Protein Structure Determination in Industry meeting, which was held at the Novotel Paris Centre Tour Eiffel in Paris, France. This year’s meeting was organized jointly by SERVIER and Synchrotron SOLEIL, with support from Hg3 Conferences. The scientific talks focused on the…

In person As in previous years, ZoBio was proud to be a sponsor of the 15th Swiss Course on Medicinal Chemistry in Leysin! This five-day Medicinal Chemistry School, organized by the Division of Medicinal Chemistry and Chemical Biology of the Swiss Chemical Society , focuses on the most cutting-edge aspects of small molecule drug discovery, highlighting…

In person For the first time, ZoBio was excited to participate in BioJapan 2024, an event held in conjunction with Regenerative Medicine Japan and healthTECH Japan. As Asia’s largest partnering event, it offers a comprehensive platform through its three main programs: exhibition, seminars, and partnering. Jan Schultz attended One-on-One meetings to share insights about our…